問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of Nuclear Medicine

更新時間：2023-09-19

林潔
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林潔

List

16Cases

2024-02-28 - 2030-03-31

Phase III

Active
A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma

  • Condition/Disease

    Peripheral T-Cell Lymphoma

  • Test Drug

    injection

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2029-07-01

Phase III

Active
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

  • Condition/Disease

    Follicular Lymphoma (FL)

  • Test Drug

    Odronextamab

Participate Sites
12Sites

Recruiting12Sites

2023-06-01 - 2028-11-27

Phase III

Active
A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronex tamab (REGN1979), an anti-CD20 × anti- CD3 bispecific antibody, in Combination with CHOP (Odro-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large Bcell Lymphoma (DLBCL) (OLYMPIA-3)

  • Condition/Disease

    Previously Untreated Participants with Diffuse Large Bcell Lymphoma (DLBCL)

  • Test Drug

    injection

Participate Sites
9Sites

Recruiting9Sites

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-04-01 - 2029-10-31

Phase III

A Randomized, 2-Arm, Phase 3 Study of Elranatamab (PF-06863135) Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    Elranatamab Lenalidomide

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2020-12-25 - 2025-07-31

Phase III

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

  • Condition/Disease

    diffuse large B-cell lymphoma (DLBCL)

  • Test Drug

    Brentuximab Vedotin, Lenalidomide,Rituximab

Participate Sites
7Sites

Recruiting7Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB